Cipla plans to invest Rs 500cr to set up API units
Cipla plans to invest Rs 500 crore to set up active pharmaceutical ingredients facilities at Patalganga, Bengaluru and Kurkumbh.
These facilities are expected to be completed by 2012-13, the pharmaceutical company said in its annual report.
According to the annual report, the several dosage forms and APIs manufactured at the company’s units continued to enjoy the approval of major regulatory agencies like WHO and USFDA.
Cipla is actively involved in developing bio- similars and bio-therapeutic products through its partners in China. It is expected that the clinical trials on these drugs will be completed in 2-3 years and subsequently, the products will be launched in India.
The company’s venture into stem cell-based products is under progress with major investment in Stempeutics Research Pvt Ltd, Bengaluru.
At present, clinical trials for regulatory approvals for some therapeutic areas are under way in India and Malaysia. The launch of the stem-cell-based products is expected in three years.
Cipla also said, the international business also continues to be a major revenue driver. During FY2011-12, over 53% of the total income originated from the global markets.
The company is also expanding its presence in the inhaler segment in Europe, with regulatory approvals for few products already in place and few more in the pipeline.
Cipla is also exploring all the options including filing its own Abbreviated New Drug Applications in the U.S.
Cipla is the Indian pharmaceutical company that manufactures low-cost anti-AIDS drugs for HIV-positive patients in developing countries. The company has also played a larger role in expanding access to the drugs to fight influenza, cancer and respiratory disease. The products of Cipla are distributed in every country of the world.
Family doctors should give COVID vaccine, survey finds
A new survey has found that doctors believe patients would be more open to receiving the COVID-19 vaccine if it was administered by a trusted doctor.
The research by Sermo, a social media network for clinicians, was carried out among 3,329 physicians from around the world. It found that nearly 70% said that if they could administer the vaccine to reluctant patients themselves, they believe they would feel more comfortable about getting vaccinated.
Additionally, nearly half of the people surveyed said that their ability to discuss the benefits of vaccination and answer patients' questions during appointments could help increase their willingness to get vaccinated.
The survey results are released as infection rates rise among people who have not received the vaccine. In the US Dr Rochelle Walensky, director of the US Centers for Disease Control and Prevention has called the latest surge "a pandemic of the unvaccinated".
Sermo’s COVID-19 Real Time Barometer also showed 65% of physicians believe that vaccinating children is essential for long-term control of the virus. Other findings include:
* 55% of physicians say their patients are more reluctant to vaccinate their children than themselves due to fear of adverse effects
* 60% believe a one-dose vial that administered at their office during appointments would be beneficial in continuing to administer vaccinations
* 81% believe that paediatricians and family doctors are in the best position to vaccinate children
Respondents also said resources and information should be created to educate their patient base and parents about the importance of getting vaccinated.
“Our survey reveals that physicians worldwide feel strongly that they can and perhaps, should, play a very important role in driving COVID vaccination uptake,” said Peter Kirk, Sermo's CEO.
“The trust they have built with their patients, combined with the ability to counsel, answer questions, ease concerns and provide assurances could help patients overcome their hesitancy to be vaccinated. Allowing physicians to vaccinate their own patients has the potential to increase vaccine rates.”